Nrx Pharmaceuticals Inc (Formerly Known As Neurorx)
DE · 4 filings, 2025
Lobbying spend · 2025
$96K
to shape legislation
About the organization
Osavampator (developmental code names TAK-653 and NBI-1065845) is an experimental drug being investigated as a treatment for treatment-resistant depression. It is being developed by Takeda Pharmaceuticals (Millennium Pharmaceuticals, Inc. via Wikipedia ↗
1Lobbies on
Its filings list: Health Issues · Medical/Disease Research/Clinical Labs · Veterans
2Through these firms · 1
TWENTY-FIRST CENTURY GROUP, INC.
3Bills moving in its lanes
No bill names this company outright; these are recent bills in the sectors it lobbies.
- S 5225A bill to amend the Elementary and Secondary Education Act of 1965 to include certain curriculum expenses a…
- S 5232A bill to amend the Public Health Service Act to authorize rural residency planning and development grant p…
- S 5237A bill to require the Director of the National Institute of Allergy and Infectious Diseases to award a comp…
- S 5242A bill to provide for digital communication of prescribing information for drugs (including biological prod…
- HR 10033Rules for self-driving cars and emergency crews